the US, battling cancer has not only been a health issue, but a considerable financial burden brought on by cancer treatment. Biosimilars are intended to be lower cost, high-quality treatment options that have the potential to alleviate such burden. We
www.swiatobrazu.pl/forumfoto/viewtopic.php?f=11&t=120079
sincerely hope our trastuzumab biosimilar will do exactly that,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis.
www.swiatobrazu.pl/forumfoto/viewtopic.php?f=11&t=256002
“At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening the availability of approved treatments for cancer patients
ginaminorallen.com/alligator/community-b...b47f5#comment-274996